Subject category:
Ethics and Social Responsibility
Published by:
IBS Research Center
Length: 11 pages
Data source: Published sources
Topics:
Tysabri; Biogen IDEC; Food and drug administration (FDA); Bio-pharmaceutical industry; Accelerated approval; Blockbuster drug; Side effects of drug; Drug withdrawal; Avonex; Multiple sclerosis (MS) patients; Clinical trials; Progressive multifocal leukoencephalopathy (PML); Multiple sclerosis; Alternative multiple sclerosis drugs; Elan
Share a link:
https://casecent.re/p/63471
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
In 2004, Biogen IDEC was the third largest bio-pharmaceutical company in the world. Biogen IDEC, in collaboration with Elan, launched Tysabri (late 2004), for the treatment of multiple sclerosis. Tysabri was supposed to be a blockbuster drug for Biogen IDEC. However, the drug was withdrawn from the market soon after its launch, due to fatal side effects. There were mixed opinions in the market about the comeback of the drug. The case highlights the US bio-pharmaceutical industry and the various stages involved in the development of a drug. The case further discusses the hyped launch of Tysabri in the US market and the impact of its withdrawal. The case can be used to examine: (1) the state of the bio-pharmaceutical industry in the US; (2) the stages of research and development and the effects of accelerated approval; (3) whether Biogen IDEC was too early in its launch of Tysabri; (4) the acceptance of Tysabri in the US market; and (5) the impact of the withdrawal of Tysabri.
About
Abstract
In 2004, Biogen IDEC was the third largest bio-pharmaceutical company in the world. Biogen IDEC, in collaboration with Elan, launched Tysabri (late 2004), for the treatment of multiple sclerosis. Tysabri was supposed to be a blockbuster drug for Biogen IDEC. However, the drug was withdrawn from the market soon after its launch, due to fatal side effects. There were mixed opinions in the market about the comeback of the drug. The case highlights the US bio-pharmaceutical industry and the various stages involved in the development of a drug. The case further discusses the hyped launch of Tysabri in the US market and the impact of its withdrawal. The case can be used to examine: (1) the state of the bio-pharmaceutical industry in the US; (2) the stages of research and development and the effects of accelerated approval; (3) whether Biogen IDEC was too early in its launch of Tysabri; (4) the acceptance of Tysabri in the US market; and (5) the impact of the withdrawal of Tysabri.